Name (Synonyms) | Correlation | |
---|---|---|
drug548 | COVID-19 Serology Wiki | 0.71 |
drug547 | COVID-19 RT-PCR Wiki | 0.58 |
There is one clinical trial.
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: the mean time patients devleoped IgM
Measure: Time to IgM Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgG Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgA Time: Evaluated within a 100 days followupDescription: Cohen's kappa coefficient calculated between the different serology kits used for evaluation
Measure: Serology kits inter-observer agreement Time: Evaluated within a 100 days followup